Effect of synbiotics on inflammatory markers and white blood cell count in COVID-19 patients: a randomized, double-blind, placebo-controlled clinical trial

Purpose Today, coronavirus disease-19 (COVID-19) treatment is an evolving process, and synbiotic administration has been suggested as a new therapeutic strategy. This study aims to investigate the effect of synbiotic supplementation in COVID-19 patients. Design/methodology/approach In this placebo-c...

Full description

Saved in:
Bibliographic Details
Published in:Nutrition and food science 2023-05, Vol.53 (4), p.714-725
Main Authors: Khodadoostan, Mahsa, Aghadavood Marnani, Majid, Moravejolahkami, Amir Reza, Askari, Gholamreza, Iraj, Bijan
Format: Article
Language:English
Subjects:
Abdomen
Antibiotics
Blood
C-reactive protein
Clinical trials
Coronaviruses
COVID-19
Cytokines
Diarrhea
Disease transmission
Double-blind studies
Erythrocyte sedimentation rate
Fructooligosaccharides
Infections
Inflammation
Interleukin 6
Intervention
Lactobacilli
Leukocytes
Lungs
Medical research
Microbiota
Patients
Placebos
Plasma
Probiotics
Severe acute respiratory syndrome coronavirus 2
Tumor necrosis factor-TNF
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c311t-4b0ad1d23457d94cb98e37a5c766040feae16aa92046060cbbf7945572497a023
cites cdi_FETCH-LOGICAL-c311t-4b0ad1d23457d94cb98e37a5c766040feae16aa92046060cbbf7945572497a023
container_end_page 725
container_issue 4
container_start_page 714
container_title Nutrition and food science
container_volume 53
creator Khodadoostan, Mahsa
Aghadavood Marnani, Majid
Moravejolahkami, Amir Reza
Askari, Gholamreza
Iraj, Bijan
description Purpose Today, coronavirus disease-19 (COVID-19) treatment is an evolving process, and synbiotic administration has been suggested as a new therapeutic strategy. This study aims to investigate the effect of synbiotic supplementation in COVID-19 patients. Design/methodology/approach In this placebo-controlled trial, 80 patients were randomized to receive oral synbiotic capsule (containing fructooligosaccharide and seven bacterial strains; Lactobacillus (L) casei, L. rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, L. acidophilus, Bifidobacterium longum, L. bulgaricus, each one 109 colony-forming units) or placebo for two months. Inflammatory markers (Interleukin-6 [IL-6], C-reactive protein [CRP], erythrocyte sedimentation rate [ESR]) and white blood cell (WBC) count were evaluated at two timepoints (baseline, two months later). The measured variables were adjusted for confounders and analyzed by SPSS v21.0. Findings All 80 enrolled patients completed the study. The study adherence was good (approximately 70%). The mean changes for IL-6 were not significant (Δ = −0.6 ± 10.4 pg/mL vs Δ = +11.2 ± 50.3 pg/mL, p > 0.05). There were no significant improvements for CRP, ESR and WBC. Originality/value Administration of synbiotics for two months did not improve inflammatory markers in COVID-19 patients.
doi_str_mv 10.1108/NFS-06-2022-0195
format article
fullrecord <record><control><sourceid>proquest_emera</sourceid><recordid>TN_cdi_proquest_journals_2817362529</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2817362529</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-4b0ad1d23457d94cb98e37a5c766040feae16aa92046060cbbf7945572497a023</originalsourceid><addsrcrecordid>eNptkUFvVCEQx4mxiWv17pHEa7ED7wGLt2Zta5PGHqpeCfB4KS0PVmDTrF_FL1s268XE02Qy_99MMj-EPlD4RCmsz79d3RMQhAFjBKjir9CKSr4mQlH5Gq0AhpEIwdUb9LbWRwDKBypX6M_lPHvXcJ5x3Scbcguu4pxwSHM0y2JaLnu8mPLkS8UmTfj5ITSPbcx5ws7HiF3epdbzeHP38-YLoQpvTQs-tfoZG1w6k5fw209neMo7Gz2xMaTebaNx3mbicmolx-j7vj4JzkTcSjDxHTqZTaz-_d96in5cXX7ffCW3d9c3m4tb4gZKGxktmIlObBi5nNTorFr7QRrupBAwwuyNp8IYxWAUIMBZO0s1ci7ZqKQBNpyij8e925J_7Xxt-jHvSuonNVtTOQjGmeopOKZcybUWP-ttCf0xe01BHxTorkCD0AcF-qCgI-dHxC--mDj9j_hH2vACMi-Ihg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2817362529</pqid></control><display><type>article</type><title>Effect of synbiotics on inflammatory markers and white blood cell count in COVID-19 patients: a randomized, double-blind, placebo-controlled clinical trial</title><source>Emerald:Jisc Collections:Emerald Subject Collections HE and FE 2024-2026:Emerald Premier (reading list)</source><creator>Khodadoostan, Mahsa ; Aghadavood Marnani, Majid ; Moravejolahkami, Amir Reza ; Askari, Gholamreza ; Iraj, Bijan</creator><creatorcontrib>Khodadoostan, Mahsa ; Aghadavood Marnani, Majid ; Moravejolahkami, Amir Reza ; Askari, Gholamreza ; Iraj, Bijan</creatorcontrib><description>Purpose Today, coronavirus disease-19 (COVID-19) treatment is an evolving process, and synbiotic administration has been suggested as a new therapeutic strategy. This study aims to investigate the effect of synbiotic supplementation in COVID-19 patients. Design/methodology/approach In this placebo-controlled trial, 80 patients were randomized to receive oral synbiotic capsule (containing fructooligosaccharide and seven bacterial strains; Lactobacillus (L) casei, L. rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, L. acidophilus, Bifidobacterium longum, L. bulgaricus, each one 109 colony-forming units) or placebo for two months. Inflammatory markers (Interleukin-6 [IL-6], C-reactive protein [CRP], erythrocyte sedimentation rate [ESR]) and white blood cell (WBC) count were evaluated at two timepoints (baseline, two months later). The measured variables were adjusted for confounders and analyzed by SPSS v21.0. Findings All 80 enrolled patients completed the study. The study adherence was good (approximately 70%). The mean changes for IL-6 were not significant (Δ = −0.6 ± 10.4 pg/mL vs Δ = +11.2 ± 50.3 pg/mL, p &gt; 0.05). There were no significant improvements for CRP, ESR and WBC. Originality/value Administration of synbiotics for two months did not improve inflammatory markers in COVID-19 patients.</description><identifier>ISSN: 0034-6659</identifier><identifier>EISSN: 1758-6917</identifier><identifier>EISSN: 0034-6659</identifier><identifier>DOI: 10.1108/NFS-06-2022-0195</identifier><language>eng</language><publisher>Bradford: Emerald Publishing Limited</publisher><subject>Abdomen ; Antibiotics ; Blood ; C-reactive protein ; Clinical trials ; Coronaviruses ; COVID-19 ; Cytokines ; Diarrhea ; Disease transmission ; Double-blind studies ; Erythrocyte sedimentation rate ; Fructooligosaccharides ; Infections ; Inflammation ; Interleukin 6 ; Intervention ; Lactobacilli ; Leukocytes ; Lungs ; Medical research ; Microbiota ; Patients ; Placebos ; Plasma ; Probiotics ; Severe acute respiratory syndrome coronavirus 2 ; Tumor necrosis factor-TNF ; Viral diseases</subject><ispartof>Nutrition and food science, 2023-05, Vol.53 (4), p.714-725</ispartof><rights>Emerald Publishing Limited</rights><rights>Emerald Publishing Limited.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-4b0ad1d23457d94cb98e37a5c766040feae16aa92046060cbbf7945572497a023</citedby><cites>FETCH-LOGICAL-c311t-4b0ad1d23457d94cb98e37a5c766040feae16aa92046060cbbf7945572497a023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Khodadoostan, Mahsa</creatorcontrib><creatorcontrib>Aghadavood Marnani, Majid</creatorcontrib><creatorcontrib>Moravejolahkami, Amir Reza</creatorcontrib><creatorcontrib>Askari, Gholamreza</creatorcontrib><creatorcontrib>Iraj, Bijan</creatorcontrib><title>Effect of synbiotics on inflammatory markers and white blood cell count in COVID-19 patients: a randomized, double-blind, placebo-controlled clinical trial</title><title>Nutrition and food science</title><description>Purpose Today, coronavirus disease-19 (COVID-19) treatment is an evolving process, and synbiotic administration has been suggested as a new therapeutic strategy. This study aims to investigate the effect of synbiotic supplementation in COVID-19 patients. Design/methodology/approach In this placebo-controlled trial, 80 patients were randomized to receive oral synbiotic capsule (containing fructooligosaccharide and seven bacterial strains; Lactobacillus (L) casei, L. rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, L. acidophilus, Bifidobacterium longum, L. bulgaricus, each one 109 colony-forming units) or placebo for two months. Inflammatory markers (Interleukin-6 [IL-6], C-reactive protein [CRP], erythrocyte sedimentation rate [ESR]) and white blood cell (WBC) count were evaluated at two timepoints (baseline, two months later). The measured variables were adjusted for confounders and analyzed by SPSS v21.0. Findings All 80 enrolled patients completed the study. The study adherence was good (approximately 70%). The mean changes for IL-6 were not significant (Δ = −0.6 ± 10.4 pg/mL vs Δ = +11.2 ± 50.3 pg/mL, p &gt; 0.05). There were no significant improvements for CRP, ESR and WBC. Originality/value Administration of synbiotics for two months did not improve inflammatory markers in COVID-19 patients.</description><subject>Abdomen</subject><subject>Antibiotics</subject><subject>Blood</subject><subject>C-reactive protein</subject><subject>Clinical trials</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cytokines</subject><subject>Diarrhea</subject><subject>Disease transmission</subject><subject>Double-blind studies</subject><subject>Erythrocyte sedimentation rate</subject><subject>Fructooligosaccharides</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Interleukin 6</subject><subject>Intervention</subject><subject>Lactobacilli</subject><subject>Leukocytes</subject><subject>Lungs</subject><subject>Medical research</subject><subject>Microbiota</subject><subject>Patients</subject><subject>Placebos</subject><subject>Plasma</subject><subject>Probiotics</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Tumor necrosis factor-TNF</subject><subject>Viral diseases</subject><issn>0034-6659</issn><issn>1758-6917</issn><issn>0034-6659</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNptkUFvVCEQx4mxiWv17pHEa7ED7wGLt2Zta5PGHqpeCfB4KS0PVmDTrF_FL1s268XE02Qy_99MMj-EPlD4RCmsz79d3RMQhAFjBKjir9CKSr4mQlH5Gq0AhpEIwdUb9LbWRwDKBypX6M_lPHvXcJ5x3Scbcguu4pxwSHM0y2JaLnu8mPLkS8UmTfj5ITSPbcx5ws7HiF3epdbzeHP38-YLoQpvTQs-tfoZG1w6k5fw209neMo7Gz2xMaTebaNx3mbicmolx-j7vj4JzkTcSjDxHTqZTaz-_d96in5cXX7ffCW3d9c3m4tb4gZKGxktmIlObBi5nNTorFr7QRrupBAwwuyNp8IYxWAUIMBZO0s1ci7ZqKQBNpyij8e925J_7Xxt-jHvSuonNVtTOQjGmeopOKZcybUWP-ttCf0xe01BHxTorkCD0AcF-qCgI-dHxC--mDj9j_hH2vACMi-Ihg</recordid><startdate>20230525</startdate><enddate>20230525</enddate><creator>Khodadoostan, Mahsa</creator><creator>Aghadavood Marnani, Majid</creator><creator>Moravejolahkami, Amir Reza</creator><creator>Askari, Gholamreza</creator><creator>Iraj, Bijan</creator><general>Emerald Publishing Limited</general><general>Emerald Group Publishing Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RQ</scope><scope>7RV</scope><scope>7X2</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>L6V</scope><scope>M0K</scope><scope>M2O</scope><scope>M7S</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope></search><sort><creationdate>20230525</creationdate><title>Effect of synbiotics on inflammatory markers and white blood cell count in COVID-19 patients: a randomized, double-blind, placebo-controlled clinical trial</title><author>Khodadoostan, Mahsa ; Aghadavood Marnani, Majid ; Moravejolahkami, Amir Reza ; Askari, Gholamreza ; Iraj, Bijan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-4b0ad1d23457d94cb98e37a5c766040feae16aa92046060cbbf7945572497a023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abdomen</topic><topic>Antibiotics</topic><topic>Blood</topic><topic>C-reactive protein</topic><topic>Clinical trials</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cytokines</topic><topic>Diarrhea</topic><topic>Disease transmission</topic><topic>Double-blind studies</topic><topic>Erythrocyte sedimentation rate</topic><topic>Fructooligosaccharides</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Interleukin 6</topic><topic>Intervention</topic><topic>Lactobacilli</topic><topic>Leukocytes</topic><topic>Lungs</topic><topic>Medical research</topic><topic>Microbiota</topic><topic>Patients</topic><topic>Placebos</topic><topic>Plasma</topic><topic>Probiotics</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Tumor necrosis factor-TNF</topic><topic>Viral diseases</topic><toplevel>online_resources</toplevel><creatorcontrib>Khodadoostan, Mahsa</creatorcontrib><creatorcontrib>Aghadavood Marnani, Majid</creatorcontrib><creatorcontrib>Moravejolahkami, Amir Reza</creatorcontrib><creatorcontrib>Askari, Gholamreza</creatorcontrib><creatorcontrib>Iraj, Bijan</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest Career &amp; Technical Education Database</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Engineering Collection</collection><collection>Agriculture Science Database</collection><collection>Proquest Research Library</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><jtitle>Nutrition and food science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khodadoostan, Mahsa</au><au>Aghadavood Marnani, Majid</au><au>Moravejolahkami, Amir Reza</au><au>Askari, Gholamreza</au><au>Iraj, Bijan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of synbiotics on inflammatory markers and white blood cell count in COVID-19 patients: a randomized, double-blind, placebo-controlled clinical trial</atitle><jtitle>Nutrition and food science</jtitle><date>2023-05-25</date><risdate>2023</risdate><volume>53</volume><issue>4</issue><spage>714</spage><epage>725</epage><pages>714-725</pages><issn>0034-6659</issn><eissn>1758-6917</eissn><eissn>0034-6659</eissn><abstract>Purpose Today, coronavirus disease-19 (COVID-19) treatment is an evolving process, and synbiotic administration has been suggested as a new therapeutic strategy. This study aims to investigate the effect of synbiotic supplementation in COVID-19 patients. Design/methodology/approach In this placebo-controlled trial, 80 patients were randomized to receive oral synbiotic capsule (containing fructooligosaccharide and seven bacterial strains; Lactobacillus (L) casei, L. rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, L. acidophilus, Bifidobacterium longum, L. bulgaricus, each one 109 colony-forming units) or placebo for two months. Inflammatory markers (Interleukin-6 [IL-6], C-reactive protein [CRP], erythrocyte sedimentation rate [ESR]) and white blood cell (WBC) count were evaluated at two timepoints (baseline, two months later). The measured variables were adjusted for confounders and analyzed by SPSS v21.0. Findings All 80 enrolled patients completed the study. The study adherence was good (approximately 70%). The mean changes for IL-6 were not significant (Δ = −0.6 ± 10.4 pg/mL vs Δ = +11.2 ± 50.3 pg/mL, p &gt; 0.05). There were no significant improvements for CRP, ESR and WBC. Originality/value Administration of synbiotics for two months did not improve inflammatory markers in COVID-19 patients.</abstract><cop>Bradford</cop><pub>Emerald Publishing Limited</pub><doi>10.1108/NFS-06-2022-0195</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0034-6659
ispartof Nutrition and food science, 2023-05, Vol.53 (4), p.714-725
issn 0034-6659
1758-6917
0034-6659
language eng
recordid cdi_proquest_journals_2817362529
source Emerald:Jisc Collections:Emerald Subject Collections HE and FE 2024-2026:Emerald Premier (reading list)
subjects Abdomen
Antibiotics
Blood
C-reactive protein
Clinical trials
Coronaviruses
COVID-19
Cytokines
Diarrhea
Disease transmission
Double-blind studies
Erythrocyte sedimentation rate
Fructooligosaccharides
Infections
Inflammation
Interleukin 6
Intervention
Lactobacilli
Leukocytes
Lungs
Medical research
Microbiota
Patients
Placebos
Plasma
Probiotics
Severe acute respiratory syndrome coronavirus 2
Tumor necrosis factor-TNF
Viral diseases
title Effect of synbiotics on inflammatory markers and white blood cell count in COVID-19 patients: a randomized, double-blind, placebo-controlled clinical trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A34%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_emera&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20synbiotics%20on%20inflammatory%20markers%20and%20white%20blood%20cell%20count%20in%20COVID-19%20patients:%20a%20randomized,%20double-blind,%20placebo-controlled%20clinical%20trial&rft.jtitle=Nutrition%20and%20food%20science&rft.au=Khodadoostan,%20Mahsa&rft.date=2023-05-25&rft.volume=53&rft.issue=4&rft.spage=714&rft.epage=725&rft.pages=714-725&rft.issn=0034-6659&rft.eissn=1758-6917&rft_id=info:doi/10.1108/NFS-06-2022-0195&rft_dat=%3Cproquest_emera%3E2817362529%3C/proquest_emera%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c311t-4b0ad1d23457d94cb98e37a5c766040feae16aa92046060cbbf7945572497a023%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2817362529&rft_id=info:pmid/&rfr_iscdi=true